Interventional Cardiology Perspective

 
 
  • Let's Not Move at a Rapid Clip to Repair the Forgotten Valve Before we expand percutaneous repair of the forgotten valve with the CE-marked TriClip or off-label use of MitraClip, don't forget about the randomized trial, cautions John Mandrola, MD.
  • Medicine Is Failing Patients With Obesity The recent spotlight on obesity and its link to increased COVID-19 mortality risk may be highlighting an issue within medicine itself, before the virus ever appeared, says Dr Yoni Freedhoff.
  • Preventing Heart Failure Post-Myocardial Infarction Although heart failure is a common complication of myocardial infarction, prognostic tools and new therapies can help manage the condition. Here are some key facts.
  • 'Cardio-COVID': Amal Mattu on COVID-19 and Matters of the Heart Dr Mattu discusses how to approach the treatment of cardiac complications in patients with COVID-19 in the emergency department.
  • Why I Founded United Physicians and Why You Should Join Frustration with the MOC process led cardiologist Paul Teirstein to found NBPAS. Since then, he has had numerous requests to help physicians organize, which he has resisted -- until now.
  • Cardiac Arrhythmia Highlights From ACC 2020   Dr Rachel Lampert of Yale University reviews key studies on cardiac arrhythmia and atrial fibrillation presented at the American College of Cardiology (ACC) 2020 Virtual Conference.
  • TAILOR-PCI and the Role of Genotype-Guided Antiplatelet Therapy   Investigators from the TAILOR PCI trial that used point-of-care genomic testing to identify clopidogrel nonresponders discuss the take-homes and why genotyping may be better than platelet function tests.
  • Cardiology in the Time of COVID-19 Being on-call in the COVID-19 era is different; interventional cardiologist Jaya Mallidi, MD, summarizes some of the current recommendations for safe practice.
  • Paclitaxel-Coated Devices on Pause for Patients With PAD   Why has Mayo Clinic placed a temporary moratorium on paclitaxel-coated devices for PAD? Radiology and cardiology experts discuss the controversy and what it will take to settle the issue.
  • Dropping Aspirin Post PCI: Are We There Yet?   Is P2Y12 inhibitor monotherapy post PCI ready to go mainstream? Michelle O'Donoghue considers the question of when to drop aspirin in the context of recent trials on antiplatelet therapy.
  • Could Colchicine Be the New Aspirin? Michel Zeitouni talks to Jean-Claude Tardif about the COLCOT series of clinical trials testing colchicine, an anti-inflammatory gout drug, for the prevention and treatment of cardiovascular disease.
  • Entering the TWILIGHT Zone of DAPT Duration   Experts from the Mayo Clinic discuss the impact of TWILIGHT, a comparison of ticagrelor monotherapy vs dual-antiplatelet therapy in post-PCI patients.
  • The War on Shock: Is Industry Leading the Charge? Protocols for patients in cardiogenic shock encourage use of mechanical circulatory support and play down palliative care, despite limited supporting data, writes interventional cardiologist Jaya Mallidi.
  • 'Frustration and Disbelief' Over Drug Shortages   Drs Robert Glatter and Paul Biddinger discuss drug shortages, including potential causes and solutions.
  • 15 Studies That Challenged Medical Dogma in 2019 Dr Eric J. Topol's favorite scientific papers challenge medicine's prevailing wisdom. These 15 papers from 2019 did just that.
  • Mandrola's Top 10 Cardiology Stories of 2019 It's probably no surprise that ISCHEMIA and the EXCEL controversy make John Mandrola's annual list for 2019. He also found good news in heart failure and has words of caution for TAVR expansion.
  • Cardiology 2019: Top Trials in Review   'It's like we're in the '90s again.' Drs Gibson and Harrington review top cardiology trials on revascularization, lipid management, and antithrombotics in part 1 of their annual wrap-up.
  • Top News From AHA 2019: Slideshow Results of the highly anticipated ISCHEMIA trial testing the true value of an early invasive strategy in stable ischemic heart disease was the breakout star of this year's scientific sessions.
  • Superiority of Surgery vs Stents in Left Main 'Unarguable'   Prof. John McMurray reviews the EXCEL 5-year data with John Mandrola. The primary composite outcome was similar for the two strategies but 'that's maybe not the most important part of the story'.
  • ISCHEMIA-CKD PI Hopes Study Doesn't Fuel the Flames of Renalism   Principal investigator Sripal Bangalore discusses ISCHEMIA-CKD and its implications for the management of patients with chronic kidney disease and stable CAD.